Growth factor delivery: How surface interactions modulate release in vitro and in vivo

Advanced Drug Delivery Reviews

Volumn 64, Issue 12, 2012, Pages 1239-1256

  King, William J ^a   Krebsbach, Paul H ^a,b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biomaterials; Ceramic polymer composites; Drug delivery; Hydrogels; Tissue engineering

Indexed keywords

BIOMATERIAL SCAFFOLDS; BONE FORMATION; CERAMIC/POLYMER COMPOSITES; CLINICAL PRACTICES; GROWTH FACTOR; GROWTH FACTOR DELIVERY; GROWTH FACTOR RELEASE; HUMAN BONES; IN-VITRO; PRECLINICAL DEVELOPMENT; SURFACE INTERACTIONS;

BIOLOGICAL MATERIALS; BIOMATERIALS; DRUG DELIVERY; HYDROGELS; TISSUE ENGINEERING;

DISEASE CONTROL;

ARGINYLGLYCYLASPARTIC ACID; BIOMATERIAL; CALCIUM PHOSPHATE; CARBOXYMETHYLCELLULOSE; CHITOSAN; COLLAGEN SPONGE; FIBROBLAST GROWTH FACTOR 2; GELATIN; HYDROXYAPATITE; POLY(N ISOPROPYLACRYLAMIDE); POLYCAPROLACTONE; POLYGLACTIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; SILANE DERIVATIVE; SOMATOMEDIN C; TISSUE SCAFFOLD; VASCULOTROPIN;

ADSORPTION; BONE DEFECT; BONE REGENERATION; CERAMICS; CHEMICAL INTERACTION; COMPOSITE MATERIAL; CONTROLLED RELEASE FORMULATION; COVALENT BOND; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; FLOW KINETICS; FRACTURE EXTERNAL FIXATION; FRACTURE HEALING; HUMAN; HYDROGEL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; REVIEW; SPINE FUSION; STATIC ELECTRICITY; THERMODYNAMICS; TISSUE ENGINEERING;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BONE MORPHOGENETIC PROTEIN 2; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; TISSUE SCAFFOLDS;

EID: 84865286755     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.03.004     Document Type: Review

References (208)

1. Johnson E.E., Urist M.R., Finerman G.A.M. Repair of segmental defects of the tibia with cancellous bone-grafts augmented with human-bone morphogenetic protein - a preliminary report. Clin. Orthop. Rel. Res. 1988, 236:249-257.
2. Johnson E.E., Urist M.R., Finerman G.A.M. Bone morphogenetic protein augmentation grafting of resistant femoral nonunions - a preliminary report. Clin. Orthop. Rel. Res. 1988, 230:257-265.
3. Johnson E.E., Urist M.R., Finerman G.A.M. Resistant nonunions and partial or complete segmental defects of long bones - treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. Clin. Orthop. Rel. Res. 1992, 277:229-237.
4. Urist M.R. Bone - formation by autoinduction. Science 1965, 150(3698):893-899.
5. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation-molecular clones and activities. Science 1988, 242(4885):1528-1534.
6. Blumenfeld I., Srouji S., Lanir Y., Laufer D., Livne E. Enhancement of bone defect healing in old rats by TGF-beta and IGF-1. Exp. Gerontol. 2002, 37(4):553-565.
7. Ripamonti U., Ferretti C., Teare J., Blann L. Transforming growth factor-beta isoforms and the induction of bone formation: implications for reconstructive craniofacial surgery. J. Craniofac. Surg. 2009, 20(5):1544-1555.
8. Howell T.H., Fiorellini J.P., Paquette D.W., Offenbacher S., Giannobile W.V., Lynch S.E. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J. Periodont. 1997, 68(12):1186-1193.
9. Park M.S., Kim S.S., Cho S.W., Choi C.Y., Kim B.S. Enhancement of the osteogenic efficacy of osteoblast transplantation by the sustained delivery of basic fibroblast growth factor. J. Biomed. Mater. Res. Part B 2006, 79B(2):353-359.
10. Ratanavaraporn J., Furuya H., Kohara H., Tabata Y. Synergistic effects of the dual release of stromal cell-derived factor-1 and bone morphogenetic protein-2 from hydrogels on bone regeneration. Biomaterials 2011, 32(11):2797-2811.
11. Street J., Bao M., deGuzman L., Bunting S., Peale F.V., Ferrara N., Steinmetz H., Hoeffel J., Cleland J.L., Daugherty A., van Bruggen N., Redmond H.P., Carano R.A.D., Filvaroff E.H. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(15):9656-9661.
12. Axelrad T.W., Einhorn T.A. Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev. 2009, 20(5-6):481-488.
13. Nevins M., Camelo M., Nevins M.L., Schenk R.K., Lynch S.E. Periodontal regeneration in humans using recombinant human platelet-derived growth Factor-BB (rhPDGF-BB) and allogenic bone. J. Periodont. 2003, 74(9):1282-1292.
14. Zara J.N., Siu R.K., Zhang X., Shen J., Ngo R., Lee M., Li W., Chiang M., Chung J., Kwak J., Wu B.M., Ting K., Soo C. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng. Part A 2011, 17(9-10):1389-1399.
15. Babitt J.L., Huang F.W., Xia Y., Sidis Y., Andrews N.C., Lin H.Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J. Clin. Invest. 2007, 117(7):1933-1939.
16. Burkus J.K., Gornet M.F., Glassman S.D., Slosar P.J., Rosner M.K., Deckey J.E., Nowak J., Hatcher B.M. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine. Spine 2011, Publish Ahead of Print. 10.1097/BRS.0b013e3182059a8c.
17. Dmitriev A.E., Lehman R.A., Symes A.J. Bone morphogenetic protein-2 and spinal arthrodesis: the basic science perspective on protein interaction with the nervous system. Spine J. 2011, 11(6):500-505.
18. FDA Food and Drug Administration Executive Summary for P050036 Medtronic's AMPLIFY TM rhBMP-2 Matrix Orthopaedic and Rehabilitation Devices Advisory Panel 2010.
19. Wozney J.M. Bone morphogenetic proteins. Prog. Growth Factor Res. 1989, 1(4):267-280.
20. Patterson J., Siew R., Herring S.W., Lin A.S.P., Guldberg R., Stayton P.S. Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration. Biomaterials 2010, 31(26):6772-6781.
21. Uludag H., D'Augusta D., Golden J., Li J., Timony G., Riedel R., Wozney J.M. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J. Biomed. Mater. Res. 2000, 50(2):227-238.
22. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur. J. Biochem. 1996, 237(1):295-302.
23. Laub M., Seul T., Schmachtenberg E., Jennissen H.P. Molecular modelling of bone morphogenetic protein-2 (BMP-2) by 3D-rapid prototyping. Materwiss Werksttech 2001, 32(12):926-930.
24. Chi E.Y., Krishnan S., Randolph T.W., Carpenter J.F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 2003, 20(9):1325-1336.
25. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J.S., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416(6880):507-511.
26. Friess W., Uludag H., Foskett S., Biron R., Sargeant C. Characterization of absorbable collagen sponges as rhBMP-2 carriers. Int. J. Pharm. 1999, 187(1):91-99.
27. Schwartz D. (2005) Development of an aqueous suspension of recombinant human bone morphogenetic protein-2 (rhBMP-2). Thesis http://edoc.ub.uni-muenchen.de/4431/1/Schwartz_Daniel.pdf.
28. Vallejo L.F., Rinas U. Optimized procedure for renaturation of recombinant human bone morphogenetic protein-2 at high protein concentration. Biotechnol. Bioeng. 2004, 85(6):601-609.
29. Luca L., Capelle M.A.H., Machaidze G., Arvinte T., Jordan O., Gurny R. Physical instability, aggregation and conformational changes of recombinant human bone morphogenetic protein-2 (rhBMP-2). Int. J. Pharm. 2010, 391(1-2):48-54.
30. Ward B.B., Brown S.E., Krebsbach P.H. Bioengineering strategies for regeneration of craniofacial bone: a review of emerging technologies. Oral Dis. 2010, 16(8):709-716.
31. Bassett C.A.L. Beneficial-effects of electromagnetic-fields. J. Cell. Biochem. 1993, 51(4):387-393.
32. Hollister S.J. Scaffold design and manufacturing: from concept to clinic. Adv. Mater. 2009, 21(32-33):3330-3342.
33. Jones A.L., Bucholz R.W., Bosse M.J., Mirza S.K., Lyon T.R., Webb L.X., Pollak A.N., Golden J.D., Valentin-Opran A., Tibial B.M.P.E.S. Recombination human BMP-2 and allograft compared with autogenous bonegraft for reconstruction of diaphyseal tibial fractures with cortical defects - a randomized, controlled trial. J. Bone Joint Surg. Am. 2006, 88A(7):1431-1441.
34. Allen R.T., Lee Y.P., Stimson E., Garfin S.R. Bone morphogenetic protein-2 (BMP-2) in the treatment of pyogenic vertebral osteomyelitis. Spine 2007, 32(26):2996-3006.
35. Tolli H., Kujala S., Jamsa T., Jalovaara P. Reindeer bone extract can heal the critical-size rat femur defect. Int. Orthop. 2011, 35(4):615-622.
36. Takaoka K., Koezuka M., Nakahara H. Telopeptide-depleted bovine skin collagen as a carrier for bone morphogenetic protein. J. Orthop. Res. 1991, 9(6):902-907.
37. Karageorgiou V., Tomkins M., Fajardo R., Meinel L., Snyder B., Wade K., Chen J., Vunjak-Novakovic G., Kaplan D.L. Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. J. Biomed. Mater. Res. A 2006, 78A(2):324-334.
38. Jarcho M. Calcium-phosphate ceramics as hard tissue prosthetics. Clin. Orthop. Rel. Res. 1981, 157:259-278.
39. Gao T., Kousinioris N., Winn S.R., Wozney J.M., Uludag H. Enhanced retention of rhBMP-2 in vivo by thermoreversible polymers. Materwiss Werksttech 2001, 32(12):953-961.
40. Constantz B.R., Ison I.C., Fulmer M.T., Poser R.D., Smith S.T., Vanwagoner M., Ross J., Goldstein S.A., Jupiter J.B., Rosenthal D.I. Skeletal repair by in-situ formation of the mineral phase of bone. Science 1995, 267(5205):1796-1799.
41. Uludag H., D'Augusta D., Palmer R., Timony G., Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J. Biomed. Mater. Res. 1999, 46(2):193-202.
42. Kempen D.H.R., Lu L., Hefferan T.E., Creemers L.B., Maran A., Classic K.L., Dhert W.J.A., Yaszemski M.J. Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials 2008, 29(22):3245-3252.
43. Arima Y., Iwata H. Effect of wettability and surface functional groups on protein adsorption and cell adhesion using well-defined mixed self-assembled monolayers. Biomaterials 2007, 28(20):3074-3082.
44. Rechendorff K., Hovgaard M.B., Foss M., Zhdanov V.P., Besenbacher F. Enhancement of protein adsorption induced by surface roughness. Langmuir 2006, 22(26):10885-10888.
45. Gessner A., Lieske A., Paulke B.R., Muller R.H. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur. J. Pharm. Biopharm. 2002, 54(2):165-170.
46. Gessner A., Lieske A., Paulke B.R., Muller R.H. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J. Biomed. Mater. Res. A 2003, 65A(3):319-326.
47. Pasche S., Voros J., Griesser H.J., Spencer N.D., Textor M. Effects of ionic strength and surface charge on protein adsorption at PEGylated surfaces. J. Phys. Chem. B 2005, 109(37):17545-17552.
48. Noh H., Vogler E.A. Volumetric interpretation of protein adsorption: competition from mixtures and the Vroman effect. Biomaterials 2007, 28(3):405-422.
49. Sadana A. Protein adsorption and inactivation on surfaces. Influence of heterogeneities. Chem. Rev. 1992, 92(8):1799-1818.
50. King W.J., Toepke M.W., Murphy W.L. Facile formation of dynamic hydrogel microspheres for triggered growth factor delivery. Acta Biomater. 2011, 7(3):975-985.
51. Louis-Ugbo J., Kim H.S., Boden S.D., Mayr M.T., Li R.C., Seeherman H., D'Augusta D., Blake C., Jiao A.P., Peckham S. Retention of I-125-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J. Orthop. Res. 2002, 20(5):1050-1059.
52. Dong X., Wang Q., Wu T., Pan H. Understanding adsorption-desorption dynamics of BMP-2 on hydroxyapatite (001) surface. Biophys. J. 2007, 93(3):750-759.
53. Zhou H., Wu T., Dong X., Wang Q., Shen J. Adsorption mechanism of BMP-7 on hydroxyapatite (001) surfaces. Biochem. Biophys. Res. Commun. 2007, 361(1):91-96.
54. Turhani D., Weissenboeck M., Stein E., Wanschitz F. Exogenous recombinant human BMP-2 has little initial effects on human osteoblastic cells cultured on collagen type I coated/noncoated hydroxyapatite ceramic granules. J. Oral Maxillofac. Surg. 2007, 65(3):485-493.
55. Boix T., Gomez-Morales J., Torrent-Burgues J., Monfort A., Pulgdomenech P., Rodriguez-Clemente R. Adsorption of recombinant human bone morphogenetic protein rhBMP-2m onto hydroxyapatite. J. Inorg. Biochem. 2005, 99(5):1043-1050.
56. Serro A.P., Bastos M., Pessoa J.C., Saramago B. Bovine serum albumin conformational changes upon adsorption on titania and on hydroxyapatite and their relation with biomineralization. J. Biomed. Mater. Res. A 2004, 70A(3):420-427.
57. Ruhe P.Q., Boerman O.C., Russel F.G.M., Mikos A.G., Spauwen P.H.M., Jansen J.A. In vivo release of rhBMP-2 loaded porous calcium phosphate cement pretreated with albumin. J. Mater. Sci. Mater. Med. 2006, 17(10):919-927.
58. Duggirala S.S., Mehta R.C., DeLuca P.P. Interaction of recombinant human bone morphogenetic protein-2 with poly(d, l lactide-co-glycolide) microspheres. Pharm. Dev. Technol. 1996, 1(1):11-19.
59. Zhang H., Migneco F., Lin C.-Y., Hollister S.J. Chemically-conjugated bone morphogenetic protein-2 on three-dimensional polycaprolactone scaffolds stimulates osteogenic activity in bone marrow stromal cells. Tissue Eng. Part A 2010, 16(11):3441-3448.
60. Schrier J.A., DeLuca P.P. Porous bone morphogenetic protein-2 microspheres: polymer binding and in vitro release. AAPS PharmSciTech 2001, 2(3):E17.
61. Lee J.S., Johnson A.J.W., Murphy W.L. A modular, hydroxyapatite-binding version of vascular endothelial growth factor. Adv. Mater. 2010, 22(48):5494-5498.
62. Suarez-Gonzalez D., Barnhart K., Saito E., Vanderby R., Hollister S.J., Murphy W.L. Controlled nucleation of hydroxyapatite on alginate scaffolds for stem cell-based bone tissue engineering. J. Biomed. Mater. Res. A 2010, 95A(1):222-234.
63. Lee J.S., Lee J.S., Murphy W.L. Modular peptides promote human mesenchymal stem cell differentiation on biomaterial surfaces. Acta Biomater. 2010, 6(1):21-28.
64. Lee J.S., Lu Y., Baer G.S., Markel M.D., Murphy W.L. Controllable protein delivery from coated surgical sutures. J. Mater. Chem. 2010, 20(40):8894-8903.
65. Lu Y., Markel M.D., Nemke B., Lee J.S., Graf B.K., Murphy W.L. Influence of hydroxyapatite-coated and growth factor-releasing interference screws on tendon-bone healing in an ovine model. Arthroscopy 2009, 25(12):1427-1434.
66. Jongpaiboonkit L., Franklin-Ford T., Murphy W.L. Mineral-coated polymer microspheres for controlled protein binding and release. Adv. Mater. 2009, 21(19):1960-1963.
67. McKay W.F., Peckham S., Badura J.M. Development of a novel compression-resistant carrier for recombinant human bone morphogenetic protein-2 (rhBMP-2) and preliminary clinical results. Bone morphogenetic proteins: from local to systemic therapeutics 2008, 7-23.
68. Gonzalez-Garcia C., Sousa S.R., Moratal D., Rico P., Salmeron-Sanchez M. Effect of nanoscale topography on fibronectin adsorption, focal adhesion size and matrix organisation. Colloids Surf. B Biointerfaces 2010, 77(2):181-190.
69. Ehlert N., Hoffmann A., Luessenhop T., Gross G., Mueller P.P., Stieve M., Lenarz T., Behrens P. Amino-modified silica surfaces efficiently immobilize bone morphogenetic protein 2 (BMP2) for medical purposes. Acta Biomater. 2011, 7(4):1772-1779.
70. Chatzinikolaidou M., Laub M., Rumpf H., Jennissen H.P. Biocoating of electropolished and ultra-hydrophilic titanium and cobalt chromium molybdenum alloy surfaces with proteins. Materwiss Werksttech 2002, 33(12):720-727.
71. Steinmueller-Nethl D., Kloss F.R., Najam-U-Haq M., Rainer M., Larsson K., Linsmeier C., Koehler G., Fehrer C., Lepperdinger G., Liu X., Memmel N., Bertel E., Huck C.W., Gassner R., Bonn G. Strong binding of bioactive BMP-2 to nanocrystalline diamond by physisorption. Biomaterials 2006, 27(26):4547-4556.
72. Hu W.-W., Elkasabi Y., Chen H.-Y., Zhang Y., Lahann J., Hollister S.J., Krebsbach P.H. The use of reactive polymer coatings to facilitate gene delivery from poly (epsilon-caprolactone) scaffolds. Biomaterials 2009, 30(29):5785-5792.
73. Han Z.J., Ostrikov K., Tan C.M., Tay B.K., Peel S.A.F. Effect of hydrophilicity of carbon nanotube arrays on the release rate and activity of recombinant human bone morphogenetic protein-2. Nanotechnology 2011, 22(29).
74. Tabata Y., Ikada Y. Protein release from gelatin matrices. Adv. Drug Deliv. Rev. 1998, 31(3):287-301.
75. Docherty-Skogh A.-C., Bergman K., Waern M.J., Ekman S., Hultenby K., Ossipov D., Hilborn J., Bowden T., Engstrand T. Bone morphogenetic protein-2 delivered by hyaluronan-based hydrogel induces massive bone formation and healing of cranial defects in minipigs. Plast. Reconstr. Surg. 2010, 125(5):1383-1392.
76. Hunt D.R., Jovanovic S.A., Wikesjo U.M.E., Wozney J.M., Bernard G.W. Hyaluronan supports recombinant human bone morphogenetic protein-2 induced bone reconstruction of advanced alveolar ridge defects in dogs. A pilot study. J. Periodont. 2001, 72(5):651-658.
77. Dulbecco R., Vogt M. Plaque formation and isolation of pure lines with poliomyelitis viruses. J. Exp. Med. 1954, 99(2):167-182.
78. Newman R.J., Francis M.J.O., Duthie R.B. Nuclear magnetic resonance studies of experimentally induced delayed fracture union. Clin. Orthop. Rel. Res. 1987, 216:253-261.
79. Hsu H.P., Zanella J.M., Peckham S.M., Spector M. Comparing ectopic bone growth induced by rhBMP-2 on an absorbable collagen sponge in rat and rabbit models. J. Orthop. Res. 2006, 24(8):1660-1669.
80. Yamamoto M., Tabata Y., Hong L., Miyamoto S., Hashimoto N., Ikada Y. Bone regeneration by transforming growth factor beta 1 released from a biodegradable hydrogel. J. Control. Release 2000, 64(1-3):133-142.
81. He X.Z., Ma J.Y., Jabbari E. Migration of marrow stromal cells in response to sustained release of stromal-derived factor-1 alpha from poly(lactide ethylene oxide fumarate) hydrogels. Int. J. Pharm. 2010, 390(2):107-116.
82. Rai B., Teoh S.H., Hutmacher D.W., Cao T., Ho K.H. Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2. Biomaterials 2005, 26(17):3739-3748.
83. Chen F.M., Wu Z.F., Wang Q.T., Wu H., Zhang Y.J., Nie X., Jin Y. Preparation of recombinant human bone morphogenetic protein-2 loaded dextran-based microspheres and their characteristics. Acta Pharmacol. Sin. 2005, 26(9):1093-1103.
84. Yamamoto M., Ikada Y., Tabata Y. Controlled release of growth factors based on biodegradation of gelatin hydrogel. J. Biomater. Sci. Polym. Ed. 2001, 12:77-88.
85. Morgan A.W., Chan L.L., Sendemir-Urkmez A., Cunningham B.T., Jamison R.D. Detection of growth factor binding to gelatin and heparin using a photonic crystal optical biosensor. Mater. Sci. Eng. C Mater. Biol. Appl. 2010, 30(5):686-690.
86. King W., Mohammed J., Murphy W. Modulating growth factor release from hydrogels via a protein conformational change. Soft Matter 2009, 5(12):2399-2406.
87. King W.J., Pytel N.J., Ng K., Murphy W.L. Triggered drug release from dynamic microspheres via a protein conformational change. Macromol. Biosci. 2010, 10(6):580-584.
88. King W.J., Toepke M.W., Murphy W.L. A general route for the synthesis of functional, protein-based hydrogel microspheres using tailored protein charge. Chem. Commun. (Camb.) 2011, 47(1):526-528.
89. Murphy W.L., Dillmore W.S., Modica J., Mrksich M. Dynamic hydrogels: translating a protein conformational change into macroscopic motion. Angew. Chem. Int. Ed. Engl. 2007, 46(17):3066-3069.
90. Sui Z.J., King W.J., Murphy W.L. Dynamic materials based on a protein conformational change. Adv. Mater. 2007, 19(20):3377-3380.
91. Sui Z.J., King W.J., Murphy W.L. Protein-based hydrogels with tunable dynamic responses. Adv. Funct. Mater. 2008, 18(12):1824-1831.
92. Shaikh Mohammed J., Murphy W.L. Bioinspired design of dynamic materials. Adv. Mater. 2009, 21(23):2361-2374.
93. Lee J., Choi W.I., Tae G., Kim Y.H., Kang S.S., Kim S.E., Kim S.-H., Jung Y., Kim S.H. Enhanced regeneration of the ligament-bone interface using a poly(L-lactide-co-epsilon-caprolactone) scaffold with local delivery of cells/BMP-2 using a heparin-based hydrogel. Acta Biomater. 2011, 7(1):244-257.
94. Chung Y.I., Ahn K.M., Jeon S.H., Lee S.Y., Lee J.H., Tae G. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J. Control. Release 2007, 121(1-2):91-99.
95. Xu X., Jha A.K., Duncan R.L., Jia X. Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2. Acta Biomater. 2011, 7(8):3050-3059.
96. Arikava-Hirasawa E., Watanabe H., Takami H., Hassell J.R., Yamada Y. Perlecan is essential for cartilage and cephalic development. Nature Genet. 1999, 23(3):354-358.
97. Hudalla G.A., Kouris N.A., Koepsel J.T., Ogle B.M., Murphy W.L. Harnessing endogenous growth factor activity modulates stem cell behavior. Integr. Biol. 2011, 3(8):832-842.
98. Koepsel J.T., Murphy W.L. Patterning discrete stem cell culture environments via localized self-assembled monolayer replacement. Langmuir 2009, 25(21):12825-12834.
99. Ackerman S.J., Mafilios M.S., Polly D.W. Economic evaluation of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion - an evidence-based modeling approach. Spine 2002, 27(16):S94-S99.
100. Hintze V., Moeller S., Schnabelrauch M., Bierbaum S., Viola M., Worch H., Scharnweber D. Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4). Biomacromolecules 2009, 10(12):3290-3297.
101. Capila I., Linhardt R.J. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 2002, 41(3):391-412.
102. Kisiday J., Jin M., Kurz B., Hung H., Semino C., Zhang S., Grodzinsky A.J. Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(15):9996-10001.
103. Mason J.M., Arndt K.M. Coiled coil domains: stability, specificity, and biological implications. ChemBioChem 2004, 5(2):170-176.
104. Stetefeld J., Jenny M., Schulthess T., Landwehr R., Engel J., Kammerer R.A. Crystal structure of a naturally occurring parallel right-handed coiled coil tetramer. Nat. Struct. Biol. 2000, 7(9):772-776.
105. Murota K., Sakamoto S., Kudo K. Reversible immobilization of protein into hydrogel using designed coiled-coil peptides. Chem. Lett. 2007, 36(11):1320-1321.
106. Zhang S., Gelain F., Zhao X. Designer self-assembling peptide nanofiber scaffolds for 3D tissue cell cultures. Semin. Cancer Biol. 2005, 15(5):413-420.
107. Reves B.T., Bumgardner J.D., Cole J.A., Yang Y.Z., Haggard W.O. Recipient of 2009 Society for Biomaterials Student Award for Outstanding Research. Master's Degree Candidate Category Lyophilization to Improve Drug Delivery for Chitosan-Calcium Phosphate Bone Scaffold Construct: A Preliminary Investigation. J. Biomed. Mater. Res. Part B 2009, 90B(1):1-10.
108. Dimar J.R., Glassman S.D., Burkus K.J., Carreon L.Y. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 2006, 31(22):2534-2539.
109. Fang F., Satulovsky J., Szleifer I. Kinetics of protein adsorption and desorption on surfaces with grafted polymers. Biophys. J. 2005, 89(3):1516-1533.
110. Dee K.C., Puleo D.A., Bizios R. An Introduction to Tissue-Biomaterial Interactions 2002.
111. King W.J., Murphy W.L. Bioinspired conformational changes: an adaptable mechanism for bio-responsive protein delivery. Polymer Chem 2011, 2(3):476-491.
112. Mitsak A.G., Kemppainen J.M., Harris M.T., Hollister S.J. Effect of polycaprolactone scaffold permeability on bone regeneration in vivo. Tissue Eng. Part A 2011, 17(13-14):1831-1839.
113. Huang X., Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 2001, 73(2-3):121-136.
114. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011, 11(6):471-491.
115. Toth J.M., Boden S.D., Burkus J.K., Badura J.M., Peckham S.M., McKay W.F. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine 2009, 34(6):539-550.
116. Boerckel J.D., Kolambkar Y.M., Dupont K.M., Uhrig B.A., Phelps E.A., Stevens H.Y., Garcia A.J., Guldberg R.E. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 2011, 32(22):5241-5251.
117. Kashiwagi K., Tsuji T., Shiba K. Directional BMP-2 for functionalization of titanium surfaces. Biomaterials 2009, 30(6):1166-1175.
118. Hiemstra C., Zhong Z.Y., van Steenbergen M.J., Hennink W.E., Feijen J. Release of model proteins and basic fibroblast growth factor from in situ forming degradable dextran hydrogels. J. Control. Release 2007, 122(1):71-78.
119. Fujioka K., Maeda M., Hojo T., Sano A. Protein release from collagen matrices. Adv. Drug Deliv. Rev. 1998, 31(3):247-266.
120. Kim J., Hefferan T.E., Yaszemski M.J., Lu L.C. Potential of hydrogels based on poly(ethylene glycol) and sebacic acid as orthopedic tissue engineering scaffolds. Tissue Eng. Part A 2009, 15(8):2299-2307.
121. Patel Z.S., Yamamoto M., Ueda H., Tabata Y., Mikos A.G. Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2. Acta Biomater. 2008, 4(5):1126-1138.
122. Kolambkar Y.M., Dupont K.M., Boerckel J.D., Huebsch N., Mooney D.J., Hutmacher D.W., Guldberg R.E. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 2011, 32(1):65-74.
123. Jha A.K., Yang W., Kirn-Safran C.B., Farach-Carson M.C., Jia X. Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 2009, 30(36):6964-6975.
124. Brown K.V., Li B., Guda T., Perrien D.S., Guelcher S.A., Wenke J.C. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release. Tissue Eng. Part A 2011, 17(13-14):1735-1746.
125. Uludag H., Friess W., Williams D., Porter T., Timony G., D'Augusta D., Blake C., Palmer R., Biron B., Wozney J. rhBMP-collagen sponges as osteoinductive devices: effects of in vitro sponge characteristics and protein pI on in vivo rhBMP pharmacokinetics. Bioartificial Organs II: Technology, Medicine, and Materials 1999, 875:369-378.
126. Jongpaiboonkit L., King W.J., Lyons G.E., Paguirigan A.L., Warrick J.W., Beebe D.J., Murphy W.L. An adaptable hydrogel array format for 3-dimensional cell culture and analysis. Biomaterials 2008, 29(23):3346-3356.
127. Jongpaiboonkit L., King W.J., Murphy W.L. Screening for 3D environments that support human mesenchymal stem cell viability using hydrogel arrays. Tissue Eng. Part A 2009, 15(2):343-353.
128. King W.J., Jongpaiboonkit L., Murphy W.L. Influence of FGF2 and PEG hydrogel matrix properties on hMSC viability and spreading. J. Biomed. Mater. Res. A 2010, 93A(3):1110-1123.
129. Beebe D.J., Mensing G.A., Walker G.M. Physics and applications of microfluidics in biology. Annu. Rev. Biomed. Eng. 2002, 4:261-286.
130. Schek R.M., Hollister S.J., Krebsbach P.H. Delivery and protection of adenoviruses using biocompatible hydrogels for localized gene therapy. Mol. Ther. 2004, 9(1):130-138.
131. Molina I., Li S.M., Martinez M.B., Vert M. Protein release from physically crosslinked hydrogels of the PLA/PEO/PLA triblock copolymer-type. Biomaterials 2001, 22(4):363-369.
132. Gao T.J., Kousinioris N.A., Wozney J.M., Winn S., Uludag H. Synthetic thermoreversible polymers are compatible with osteoinductive activity of recombinant human bone morphogenetic protein 2. Tissue Eng. 2002, 8(3):429-440.
133. Gil E.S., Hudson S.M. Stimuli-responsive polymers and their bioconjugates. Prog. Polym. Sci. 2004, 29(12):1173-1222.
134. Yamamoto M., Tabata Y., Ikada Y. Ectopic bone formation induced by biodegradable hydrogels incorporating bone morphogenetic protein. J. Biomat. Sci.-Polym. E 1998, 9(5):439-458.
135. Einerson N.J., Stevens K.R., Kao W.Y.J. Synthesis and physicochemical analysis of gelatin-based hydrogels for drug carrier matrices. Biomaterials 2003, 24(3):509-523.
136. Zhang L., Furst E.M., Kiick K.L. Manipulation of hydrogel assembly and growth factor delivery via the use of peptide-polysaccharide interactions. J. Control. Release 2006, 114(2):130-142.
137. Holmgren S.K., Bretscher L.E., Taylor K.M., Raines R.T. A hyperstable collagen mimic. Chem. Biol. 1999, 6(2):63-70.
138. Li C.F., McCarthy J.B., Furcht L.T., Fields G.B. An all-D amino acid peptide model of alpha 1(IV)531-543 from type IV collagen binds the alpha(3)beta(1) integrin and mediates tumor cell adhesion, spreading, and motility. Biochemistry 1997, 36(49):15404-15410.
139. Lutolf M.P., Lauer-Fields J.L., Schmoekel H.G., Metters A.T., Weber F.E., Fields G.B., Hubbell J.A. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. P Natl Acad Sci USA 2003, 100(9):5413-5418.
140. Segers V.F.M., Tokunou T., Higgins L.J., MacGillivray C., Gannon J., Lee R.T. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116(15):1683-1692.
141. Zisch A.H., Lutolf M.P., Ehrbar M., Raeber G.P., Rizzi S.C., Davies N., Schmokel H., Bezuidenhout D., Djonov V., Zilla P., Hubbell J.A. Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth. FASEB J. 2003, 17(13):2260-2262.
142. Henle P., Zimmermann G., Weiss S. Matrix metalloproteinases and failed fracture healing. Bone 2005, 37(6):791-798.
143. Lee K.Y., Peters M.C., Anderson K.W., Mooney D.J. Controlled growth factor release from synthetic extracellular matrices. Nature 2000, 408(6815):998-1000.
144. Seeherman H.J., Li X.J., Bouxsein M.L., Wozney J.M. rhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J. Bone Joint Surg. Am. 2010, 92A(2):411-426.
145. Zhao X., Kim J., Cezar C.A., Huebsch N., Lee K., Bouhadir K., Mooney D.J. Active scaffolds for on-demand drug and cell delivery. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(1):67-72.
146. Bromberg L.E., Ron E.S. Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery. Adv. Drug Deliv. Rev. 1998, 31(3):197-221.
147. Yamamoto M., Takahashi Y., Tabata Y. Controlled release by biodegradable hydrogyels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 2003, 24(24):4375-4383.
148. Vroman L., Adams A.L. Identification of rapid changes at plasma-solid interfaces. J. Biomed. Mater. Res. 1969, 3(1):43-67.
149. Yeung D.K.W., Wong S.Y.S., Griffith J.F., Lau E.M.C. Bone marrow diffusion in osteoporosis: evaluation with quantitative MR diffusion imaging. J. Magn. Reson. Imaging 2004, 19(2):222-228.
150. Alaoui-Ismaili M.H., Falb D. Design of second generation therapeutic recombinant bone morphogenetic proteins. Cytokine Growth Factor Rev. 2009, 20(5-6):501-507.
151. Tazaki J., Murata M., Akazawa T., Yamamoto M., Ito K., Arisue M., Shibata T., Tabata Y. BMP-2 release and dose-response studies in hydroxyapatite and beta-tricalcium phosphate. Biomed. Mater. Eng. 2009, 19(2-3):141-146.
152. Seeherman H.J., Archambault J.M., Rodeo S.A., Turner A.S., D'Augusta D., Li X.J., Smith E., Wozney J.M. rhBMP-12 accelerates healing of rotator cuff repairs in a sheep model. J. Bone Joint Surg. Am. 2008, 90A(10):2206-2219.
153. Peppas N.A., Hilt J.Z., Khademhosseini A., Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv. Mater. 2006, 18(11):1345-1360.
154. Kinsella C.R., Bykowski M.R., Lin A.Y., Cray J.J., Durham E.L., Smith D.M., DeCesare G.E., Mooney M.P., Cooper G.M., Losee J.E. BMP-2-mediated regeneration of large-scale cranial defects in the canine: an examination of different carriers. Plast. Reconstr. Surg. 2011, 127(5):1865-1873.
155. Medtronic Sofamor Danek Premarket Approval Application InFUSE ™ Bone Graft/LT-CAGE™ Lumbar Tapered Fusion Device. (Application Number: P000058) 2002.
156. Vihola H., Laukkanen A., Valtola L., Tenhu H., Hirvonen J. Cytotoxicity of thermosensitive polymers poly(N-isopropylacrylamide), poly(N-vinylcaprolactam) and amphiphilically modified poly(N-vinylcaprolactam). Biomaterials 2005, 26(16):3055-3064.
157. Yamamoto M., Takahashi Y., Tabata Y. Bone induction by controlled release of BMP-2 from a biodegradable hydrogel in various animal species - from mouse to non-human primate. Asbm6: Advanced Biomaterials VI 2005, 288-289:253-256.
158. Hu W.W., Ward B.B., Wang Z., Krebsbach P.H. Bone regeneration in defects compromised by radiotherapy. J. Dent. Res. 2010, 89(1):77-81.
159. Alanay A., Chen C.H., Lee S., Murray S.S., Brochmann E.J., Miyazaki M., Napoli A., Wang J.C. The adjunctive effect of a binding peptide on bone morphogenetic protein enhanced bone healing in a rodent model of spinal fusion. Spine 2008, 33(16):1709-1713.
160. Behnam K., Phillips M.L., Sliva J.D.P., Brochmann E.J., Duarte M.E.L., Murray S.S. BMP binding peptide: a BMP-2 enhancing factor deduced from the sequence of native bovine bone morphogenetic protein/non-collagenous protein. J. Orthop. Res. 2005, 23(1):175-180.
161. Lee K.B., Murray S.S., Taghavi C.E., Song K.J., Brochmann E.J., Johnson J.S., Keorochana G., Liao J.C., Wang J.C. Bone morphogenetic protein-binding peptide reduces the inflammatory response to recombinant human bone morphogenetic protein-2 and recombinant human bone morphogenetic protein-7 in a rodent model of soft-tissue inflammation. Spine J. 2011, 11(6):568-576.
162. Taghavi C.E., Lee K.-B., He W., Keorochana G., Murray S.S., Brochmann E.J., Uludag H., Behnam K., Wang J.C. Bone morphogenetic protein binding peptide mechanism and enhancement of osteogenic protein-1 induced bone healing. Spine 2010, 35(23):2049-2056.
163. Takahashi Y., Yamamoto M., Yamada K., Kawakami O., Tabata Y. Skull bone regeneration in nonhuman primates by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng. 2007, 13(2):293-300.
164. Seeherman H., Kirker-Head C., Li X., Bouxsein M.L., Wozney J. rhBMP-2 stimulates bone formation in a femoral head core decompression model in adult sheep. Transactions of the 44th Annual Meeting of the Orthopaedic Research Society 1998.
165. Dickerman R.D., Reynolds A.S., Morgan B.C., Tompkins J., Cattorini J., Bennett M. rh-BMP-2 can be used safely in the cervical spine: dose and containment are the keys!. Spine J. 2007, 7(4):508-509.
166. Seeherman H., Li R., Bouxsein M., Kim H., Li X.J., Smith-Adaline E.A., Aiolova M., Wozney J.M. rhBMP-2/calcium phosphate matrix accelerates osteotomy-site healing in a nonhuman primate model at multiple treatment times and concentrations. J. Bone Joint Surg. Am. 2006, 88A(1):144-160.
167. Klimo P., Peelle M.W. Use of polyetheretherketone spacer and recombinant human bone morphogenetic protein-2 in the cervical spine: a radiographic analysis. Spine J. 2009, 9(12):959-966.
168. Martin G.J., Boden S.D., Morone M.A., Moskovitz Y.A. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J. Spinal Disord. 1999, 12(3):179-186.
169. Bouxsein M.L., Turek T.J., Blake C.A., D'Augusta D., Li X., Stevens M., Seeherman H.J., Wozney J.M. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J. Bone Joint Surg. Am. 2001, 83A(8):1219-1230.
170. Akamaru T., Suh D., Boden S.D., Kim H.S., Minamide A., Louis-Ugbo J. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine 2003, 28(5):429-434.
171. Richardson T.P., Peters M.C., Ennett A.B., Mooney D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol. 2001, 19(11):1029-1034.
172. Huang Y.C., Kaigler D., Rice K.G., Krebsbach P.H., Mooney D.J. Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. J. Bone Miner. Res. 2005, 20(5):848-857.
173. Kempen D.H.R., Lu L., Heijink A., Hefferan T.E., Creemers L.B., Maran A., Yaszemski M.J., Dhert W.J.A. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials 2009, 30(14):2816-2825.
174. Springer I.N.G., Niehoff P., Acil Y., Marget M., Lange A., Warnke P.H., Pielenz H., Roldan J.C., Wiltfang J. BMP-2 and bFGF in an irradiated bone model. J. Cranio Maxill Surg. 2008, 36(4):210-217.
175. Lan J., Wang Z., Wang Y., Wang J., Cheng X. The effect of combination of recombinant human bone morphogenetic and protein-2 and basic fibroblast growth factor or insulin-like growth factor-I on dental implant osseointegration by confocal laser scanning microscopy. J. Periodont. 2006, 77(3):357-363.
176. Canalis E. Growth factor control of bone mass. J. Cell. Biochem. 2009, 108(4):769-777.
177. Shiozawa Y., Jung Y., Ziegler A.M., Pedersen E.A., Wang J., Wang Z., Song J., Wang J., Lee C.H., Sud S., Pienta K.J., Krebsbach P.H., Taichman R.S. Erythropoietin couples hematopoiesis with bone formation. PLoS One 2010, 5(5).
178. Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987, 316(2):73-78.
179. Kempen D.H.R., Lu L., Hefferan T.E., Creemers L.B., Heijink A., Maran A., Dhert W.J.A., Yaszemski M.J. Enhanced bone morphogenetic protein-2-induced ectopic and orthotopic bone formation by intermittent parathyroid hormone (1-34) administration. Tissue Eng. Part A 2010, 16(12):3769-3777.
180. Krebsbach P.H., Kuznetsov S.A., Bianco P., Robey P.G. Bone marrow stromal cells: characterization and clinical application. Crit. Rev. Oral Biol. Med. 1999, 10(2):165-181.
181. Krebsbach P.H., Zhang K.Z., Malik A.K., Kurachi K. Bone marrow stromal cells as a genetic platform for systemic delivery of therapeutic proteins in vivo: human factor IX model. J. Gene Med. 2003, 5(1):11-17.
182. Nussenbaum B., Krebsbach P.H. The role of gene therapy for craniofacial and dental tissue engineering. Adv. Drug Deliv. Rev. 2006, 58(4):577-591.
183. Peterson B., Zhang J., Iglesias R., Kabo M., Hedrick M., Benhaim P., Lieberman J.R. Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue. Tissue Eng. 2005, 11(1-2):120-129.
184. Ekrol I., Hajducka C., Court-Brown C., McQueen M.M. A comparison of RhBMP-7 (OP-1) and autogenous graft for metaphyseal defects after osteotomy of the distal radius. Injury-Int. J. Care Inj. 2008, 39:S73-S82.
185. Chen X.Q., Kidder L.S., Lew W.D. Osteogenic protein-1 induced bone formation in an infected segmental defect in the rat femur. J. Orthop. Res. 2002, 20(1):142-150.
186. Southwood L.L., Frisbie D.D., Kawcak C.E., Ghivizzani S.C., Evans C.H., McIlwraith C.W. Evaluation of Ad-BMP-2 for enhancing fracture healing in an infected defect fracture rabbit model. J. Orthop. Res. 2004, 22(1):66-72.
187. Horii A., Wang X., Gelain F., Zhang S. Biological designer self-assembling peptide nanofiber scaffolds significantly enhance osteoblast proliferation, differentiation and 3-D migration. PLoS One 2007, 2(2).
188. Gelain F., Unsworth L.D., Zhang S. Slow and sustained release of active cytokines from self-assembling peptide scaffolds. J. Control. Release 2010, 145(3):231-239.
189. Chau Y., Luo Y., Cheung A.C.Y., Nagai Y., Zhang S., Kobler J.B., Zeitels S.M., Langer R. Incorporation of a matrix metalloproteinase-sensitive substrate into self-assembling peptides - a model for biofunctional scaffolds. Biomaterials 2008, 29(11):1713-1719.
190. Nakahara H., Misawa H., Yoshida A., Hayashi T., Tanaka M., Furumatsu T., Tanaka N., Kobayashi N., Ozaki T. Bone repair using a hybrid scaffold of self-assembling peptide puramatrix and polyetheretherketone cage in rats. Cell Transplant. 2010, 19(6-7):791-797.
191. Hollister S.J., Murphy W.L. Scaffold translation: barriers between concept and clinic. Tissue Eng. B 2011, 17(6):459-474.
192. Schuckert K.H., Jopp S., Teoh S.H. Mandibular defect reconstruction using three-dimensional polycaprolactone scaffold in combination with platelet-rich plasma and recombinant human bone morphogenetic protein-2: de novo synthesis of bone in a single case. Tissue Eng. Part A 2009, 15(3):493-499.
193. Murphy W.L., Kohn D.H., Mooney D.J. Growth of continuous bonelike mineral within porous poly(lactide-co-glycolide) scaffolds in vitro. J. Biomed. Mater. Res. 2000, 50(1):50-58.
194. Murphy W.L., Mooney D.J. Bioinspired growth of crystalline carbonate apatite on biodegradable polymer substrata. J. Am. Chem. Soc. 2002, 124(9):1910-1917.
195. Suarez-Gonzalez D., Barnhart K., Migneco F., Flanagan C., Hollister S.J., Murphy W.L. Controllable mineral coatings on PCL scaffolds as carriers for growth factor release. Biomaterials 2012, 33(2):713-721.
196. Hu W.W., Elkasabi Y., Chen H.Y., Zhang Y., Lahann J., Hollister S.J., Krebsbach P.H. The use of reactive polymer coatings to facilitate gene delivery from poly (epsilon-caprolactone) scaffolds. Biomaterials 2009, 30(29):5785-5792.
197. Elkasabi Y.M., Lahann J., Krebsbach P.H. Cellular transduction gradients via vapor-deposited polymer coatings. Biomaterials 2011, 32(7):1809-1815.
198. Ito Y. Covalently immobilized biosignal molecule materials for tissue engineering. Soft Matter 2008, 4(1):46-56.
199. Masters K.S. Covalent growth factor immobilization strategies for tissue repair and regeneration. Macromol. Biosci. 2011, 11(9):1149-1163.
200. Tsujigiwa H., Nagatsuka H., Gunduz M., Rodriguez A., Rivera R.S., LeGeros R.Z., Inoue M., Nagai N. Effects of immobilized recombinant human bone morphogenetic protein-2/succinylated type I atelocollagen on cellular activity of ST2 cells. J. Biomed. Mater. Res. A 2005, 75A(1):210-215.
201. Tsujigiwa H., Nagatsuka H., Lee Y.J., Han P.P., Gunduz M., LeGeros R.Z., Inoue M., Yamada M., Nagai N. Immobilized rhBMP-2/succinylated type I atelocollagen gene expression of intracellular signaling molecules on ST2 cells. J. Biomed. Mater. Res. A 2006, 77A(3):507-511.
202. Liu H.W., Chen C.H., Tsai C.L., Lin I.H., Hsiue G.H. Heterobifunctional poly(ethylene glycol)-tethered bone morphogenetic protein-2-stimulated bone marrow mesenchymal stromal cell differentiation and osteogenesis. Tissue Eng. 2007, 13(5):1113-1124.
203. Puleo D.A., Kissling R.A., Sheu M.S. A technique to immobilize bioactive proteins, including bone morphogenetic protein-4 (BMP-4), on titanium alloy. Biomaterials 2002, 23(9):2079-2087.
204. Lorenz C., Hoffmann A., Gross G., Windhagen H., Dellinger P., Mohwald K., Dempwolf W., Menzel H. Coating of titanium implant materials with thin polymeric films for binding the signaling protein BMP2. Macromol. Biosci. 2011, 11(2):234-244.
205. Hu J.L., Duppatla V., Harth S., Schmitz W., Sebald W. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues. Bioconjug. Chem. 2010, 21(10):1762-1772.
206. Kinstler O., Molineux G., Treuheit M., Ladd D., Gegg C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 2002, 54(4):477-485.
207. Hu J.L., Sebald W. N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH. Int. J. Pharm. 2011, 413(1-2):140-146.
208. Link A.J., Mock M.L., Tirrell D.A. Non-canonical amino acids in protein engineering. Curr. Opin. Biotechnol. 2003, 14(6):603-609.